JAGUAR HEALTH INC (JAGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.37-11.56%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Reduce EPS loss from -$4.20 in 2026 to less negative levels: FY27 EPS -9.45 vs trip < -9.0.
Jaguar Health aims to secure a $40M equity line of credit to improve finances. Revenue is expected around $20.5M in 2026. Recent positive M&A deals may support growth. Management is working to address Nasdaq compliance.
The company is loss-making with EPS of -$4.20 in 2026 and worsening to -$9.45 in 2027. Revenue is forecast to decline to $14.1M in 2027. Capital allocation remains mixed and financial risks persist. The stock has fallen over 80% from highs.
The market reflects a distressed biotech with no clear earnings or revenue growth priced in. Our view aligns with the weak outlook but sees some potential if capital and compliance goals are met.
Breaks if: failure to secure or draw on $40M equity line by mid-2026
Breaks if: EPS loss worsens beyond -$9 in FY27
failure to address Nasdaq compliance leading to delisting
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is in a volatile phase, with management focusing on developing new products and expanding revenue through licensing agreements.
The market appears to be pricing in a high level of risk, given the company's loss-making status and fragile earnings quality. There is an expectation of continued revenue growth, but any negative guidance could lead to significant downward adjustments.
Fundamentals may show strong performance in the near term, driven by recent revenue growth from licensing agreements. However, there is an elevated risk of an earnings miss, which could impact future performance.
The thesis hinges on management's ability to meet regulatory milestones for product development and the overall health of the healthcare sector. Key factors include guidance updates and the performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. The company plans to develop crofelemer powder for rare intestinal failure. This drug application enhances product commercialization prospects. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $14M in FY27
In the next 1 to 3 years, JAGX's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.